SEC Form 4	
------------	--

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

Check this box if no long Section 16. Form 4 or F obligations may continu	orm 5
Instruction 1(b).	e. 3ee

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol PROTEON THERAPEUTICS INC [PRTO]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Gottlied Dan	<u>iei Philip</u>				Director	10% Owner			
p				x	Officer (give title	Other (specify			
(Last)	PROTEON T (First) (Middle) COTEON THERAPEUTICS 3. Date of Earliest 01/07/2015 EST STREET 4. If Amendment, D		3. Date of Earliest Transaction (Month/Day/Year)		below)	below)			
. ,	. ,	()	01/07/2015		VP Marketing & Bu	siness Dev't			
C/O PROTEON	THERAPEUTICS	>							
200 WEST STR	EET								
			4. If Amendment, Date of Original Filed (Month/Day/Year)		ridual or Joint/Group Filing	g (Check Applicable			
(Street)				Line)					
WALTHAM	MΔ	02451		X	Form filed by One Repo	orting Person			
WALITIAN	IVIA	02431			Form filed by More thar	n One Reporting			
					Person				
(City)	(State)	(Zip)							
			1	1					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities A Disposed Of (5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Expiration		Expiration Da	ate Exercisable and iration Date nth/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$10.61	01/07/2015		A		26,699		(1)	01/06/2025	Common Stock	26,699	\$0	26,699	D	

Explanation of Responses:

1. The shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.

Remarks:

/s/ George Eldridge, attorneyin-fact

01/08/2015

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.